oday, Shire is the leading global biotechnology company focused on serving people with rare diseases.
We trace our origins back to 1986, when a small team of entrepreneurs founded the company to seek out solutions to address a number of unmet medical needs. Within the first two years of operation, we launched a range of supplemental calcium products for patients seeking to treat or prevent osteoporosis. Soon after, the company had innovative drug development programs under way on behalf of patients facing challenging conditions such as Alzheimer's disease and end-stage renal failure.
By the mid-90s, we had embarked on the first of what would be a series of strategic acquisitions to expand into new areas, develop our clinical pipeline and bring new products to market. Since those early years, we have continued to grow dramatically through the completion of more than 20 combinations over the past two-plus decades.